As discussed above, HDAC6 is an important AD therapeutic target, and previous research has shown that the selective HDAC6 inhibitors tubastatin A and ACY-1215 could improve cognitive performance in AD mice [76]. This evidence concerns the gene HDAC6 and Alzheimer disease.